- Home
- NAUT vs FHTX Comparison
NAUT vs FHTX Comparison
Compare NAUT & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAUT
- FHTX
- Stock Information
- Founded
- NAUT 2016
- FHTX 2015
- Country
- NAUT United States
- FHTX United States
- Employees
- NAUT N/A
- FHTX N/A
- Industry
- NAUT Biotechnology: Laboratory Analytical Instruments
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- NAUT Industrials
- FHTX Health Care
- Exchange
- NAUT Nasdaq
- FHTX Nasdaq
- Market Cap
- NAUT 284.7M
- FHTX 237.4M
- IPO Year
- NAUT N/A
- FHTX 2020
- Fundamental
- Price
- NAUT $2.04
- FHTX $4.41
- Analyst Decision
- NAUT Hold
- FHTX Strong Buy
- Analyst Count
- NAUT 3
- FHTX 5
- Target Price
- NAUT $3.58
- FHTX $13.80
- AVG Volume (30 Days)
- NAUT 165.9K
- FHTX 170.9K
- Earning Date
- NAUT 02-26-2025
- FHTX 03-06-2025
- Dividend Yield
- NAUT N/A
- FHTX N/A
- EPS Growth
- NAUT N/A
- FHTX N/A
- EPS
- NAUT N/A
- FHTX N/A
- Revenue
- NAUT N/A
- FHTX $25,515,000.00
- Revenue This Year
- NAUT N/A
- FHTX N/A
- Revenue Next Year
- NAUT N/A
- FHTX $7.37
- P/E Ratio
- NAUT N/A
- FHTX N/A
- Revenue Growth
- NAUT N/A
- FHTX N/A
- 52 Week Low
- NAUT $1.61
- FHTX $2.70
- 52 Week High
- NAUT $3.12
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- NAUT 58.55
- FHTX 34.76
- Support Level
- NAUT $1.89
- FHTX $4.13
- Resistance Level
- NAUT $2.00
- FHTX $4.47
- Average True Range (ATR)
- NAUT 0.11
- FHTX 0.35
- MACD
- NAUT 0.05
- FHTX 0.07
- Stochastic Oscillator
- NAUT 86.00
- FHTX 30.77
About NAUT Nautilus Biotechnolgy Inc.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. It has built a prototype of a single-molecule instrument, Proteomic Analysis System.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.